Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Calix[4]arene compound 0118 is an angiostatic agent that inhibits tumor growth in mice. Although 0118 is a topomimetic of galectin-1-targeting angiostatic amphipathic peptide Anginex, we had yet to prove that 0118 targets galectin-1. Galectin-1 is involved in pathological disorders like tumor endothelial cell adhesion and migration and therefore presents a relevant target for therapeutic intervention against cancer. Here, (15)N-(1)H HSQC NMR spectroscopy demonstrates that 0118 indeed targets galectin-1 at a site away from the lectin's carbohydrate binding site and thereby attenuates lactose binding to the lectin. Flow cytometry and agglutination assays show that 0118 attenuates binding of galectin-1 to cell surface glycans, and the inhibition of cell proliferation by 0118 is found to be correlated with the cellular expression of the lectin. In general, our data indicate that 0118 targets galectin-1 as an allosteric inhibitor of glycan/carbohydrate binding. This work contributes to the clinical development of antitumor calixarene compound 0118.

[1]  Flavia E. Popescu,et al.  Enhancement of T-cell–Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer , 2011, Clinical Cancer Research.

[2]  I. Bièche,et al.  Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer Cells , 2010, Molecular Cancer Therapeutics.

[3]  K. Mayo,et al.  Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. , 2010, Bioconjugate chemistry.

[4]  A. Klyosov,et al.  The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. , 2009, Glycobiology.

[5]  I. Bièche,et al.  Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. , 2009, Cancer research.

[6]  L. Baum,et al.  1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer , 2008, Biomolecular NMR assignments.

[7]  K. Mayo,et al.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. , 2008, Cancer letters.

[8]  G. Rabinovich,et al.  Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.

[9]  Ruud P. M. Dings,et al.  Understanding Galectin Structure-Function Relationships to Design Effective Antagonists , 2008 .

[10]  S. Monti,et al.  The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma , 2007, Proceedings of the National Academy of Sciences.

[11]  K. Mayo,et al.  A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. , 2007, Accounts of chemical research.

[12]  Ruud P. M. Dings,et al.  Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization , 2007, Clinical Cancer Research.

[13]  R. Reis,et al.  Effect of the labelling ratio on the photophysics of fluorescein isothiocyanate (FITC) conjugated to bovine serum albumin , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[14]  R. Kiss,et al.  Anti-galectin compounds as potential anti-cancer drugs. , 2006, Current medicinal chemistry.

[15]  Ruud P. M. Dings,et al.  Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy , 2006, Proceedings of the National Academy of Sciences.

[16]  R. Roy,et al.  A first QSAR model for galectin-3 glycomimetic inhibitors based on 3D docked structures. , 2006, Medicinal chemistry.

[17]  U. Nilsson,et al.  Synthesis of multivalent lactose derivatives by 1,3-dipolar cycloadditions: selective galectin-1 inhibition. , 2006, Carbohydrate research.

[18]  A. Griffioen,et al.  Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. , 2006, Journal of the National Cancer Institute.

[19]  Sachiko Sato,et al.  Aryl O- and S-galactosides and lactosides as specific inhibitors of human galectins-1 and -3: role of electrostatic potential at O-3. , 2006, Bioorganic & medicinal chemistry letters.

[20]  N. Tinari,et al.  Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. , 2006, Glycobiology.

[21]  U. Nilsson,et al.  Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors. , 2006, Bioorganic & medicinal chemistry.

[22]  J. Braekman,et al.  A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. , 2006, Journal of medicinal chemistry.

[23]  J. Keeler.  Understanding NMR Spectroscopy , 2005 .

[24]  U. Nilsson,et al.  C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. , 2005, Angewandte Chemie.

[25]  U. Nilsson,et al.  3-(1,2,3-Triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3. , 2005, Bioorganic & medicinal chemistry letters.

[26]  Benhur Lee,et al.  Novel Innate Immune Functions for Galectin-1: Galectin-1 Inhibits Cell Fusion by Nipah Virus Envelope Glycoproteins and Augments Dendritic Cell Secretion of Proinflammatory Cytokines1 , 2005, The Journal of Immunology.

[27]  A. Griffioen,et al.  Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells , 2005, International journal of cancer.

[28]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[29]  U. Nilsson,et al.  Synthesis of a phenyl thio-beta-D-galactopyranoside library from 1,5-difluoro-2,4-dinitrobenzene: discovery of efficient and selective monosaccharide inhibitors of galectin-7. , 2005, Organic & biomolecular chemistry.

[30]  U. Nilsson,et al.  Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[31]  Hans-Joachim Gabius,et al.  Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. , 2004, Journal of molecular biology.

[32]  Mariano J. Alvarez,et al.  Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. , 2004, Cancer cell.

[33]  A. Griffioen,et al.  Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity* , 2003, Journal of Biological Chemistry.

[34]  A. Griffioen,et al.  Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. , 2003, The Biochemical journal.

[35]  Ruud P. M. Dings,et al.  Anti-tumor activity of the novel angiogenesis inhibitor anginex. , 2003, Cancer letters.

[36]  Ruud P. M. Dings,et al.  The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. , 2003, Cancer research.

[37]  R. Beets-Tan,et al.  The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  I. Bièche,et al.  Quantification of estrogen receptor α and β expression in sporadic breast cancer , 2001, Oncogene.

[39]  M. Saier,et al.  Demonstration of protein—protein interaction specificity by NMR chemical shift mapping , 1997, Protein science : a publication of the Protein Society.

[40]  L. Baum,et al.  Apoptosis of T cells mediated by galectin-1 , 1995, Nature.

[41]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[42]  R. Lotan,et al.  Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. , 1991, Carbohydrate research.

[43]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[44]  Bruce A Johnson,et al.  Using NMRView to visualize and analyze the NMR spectra of macromolecules. , 2004, Methods in molecular biology.

[45]  I. Bièche,et al.  Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. , 2001, Oncogene.

[46]  S. Barondes,et al.  Galectins: a family of animal beta-galactoside-binding lectins. , 1994, Cell.